RT - European Journal of Gynaecological Oncology ID - 10.12892/ejgo4514.2019 T1 - Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients A1 - B. Soltész A1 - J. Lukács A1 - A. Penyige A1 - R. Póka A1 - B. Nagy K1 - miRNA; miR-193b; SNP K1 - Gene expression; Ovarian cancer; Melting curve analysis YR - 2019 SP - 547 AB -

Background: Single nucleotide polymorphism (SNP) is the most common form of genetic variability. The miR-193b was connected to several types of tumors and also with occurrence of resistance to chemotherapy. This investigation aimed to determine miR-193b rs30236 polymorphism in ovarian cancer patients and controls. The authors performed bioinformatics analysis to discover the target genes of miR-193b. Materials and Methods: Eighty-six ovarian cancer patients and 102 matched controls were included in the study. Blood samples were drown into EDTA tubes and DNA was isolated by silica adsorption method. Mir-193b rs30236C/T polymorphism was determined by melting curve analysis. Chi-square test was used for statistical evaluation of the data. MiRTargetLink was used for determination of the has-miR-193b-3p microRNA target genes. Results: Based on melting curve analysis of miR-193b rs30236, the authors found 30.24% T allele frequency in the patients’ group, and 35.78% in the control group (p = 0.2549). They detected CC genotype in 39.22%, CT genotype in 50.00%, and TT genotype in 10.78% of controls, while they occurred in 45.35%, 48.84%, and 5.81% of the patients (p = 0.4096), respectively. The most important target genes of miR-193b are cyclin D1 (CCND1), estrogen receptor (ESR1), plasminogen activator (PLAU), prolin rich acidic protein (PRAP1), and myeloid leukemia sequence (MCL1). Conclusions: The miR-193b has effect on the expression of several genes. The rs30236 polymorphism has not been studied in ovarian cancer patients, yet. The authors did not find significant difference in allele and genotype difference in patients and controls. To discover the exact role and suitability of this SNP for use as biomarker in the ovarian cancer prior to chemotherapy, more detailed studies are needed.